We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
Read MoreHide Full Article
Key Takeaways
Ocugen completes enrollment and dosing in the GARDian3 study of OCU410ST ahead of schedule.
OCGN's gene therapy targets Stargardt disease, a rare condition with no FDA-approved treatments.
The study evaluates safety, lesion reduction and vision endpoints, with interim data expected in Q3 2026.
Ocugen (OCGN - Free Report) announced that enrollment and dosing have been completed in the phase II/III GARDian3 pivotal confirmatory study evaluating its pipeline candidate, OCU410ST, for the treatment of Stargardt disease. The milestone was achieved in less than nine months, ahead of schedule.
OCU410ST has the potential to address more than 1,200 disease-causing mutations in the ABCA4 gene linked to Stargardt disease and other ABCA4-related retinopathies with a single, one-time treatment.
Stargardt disease type I is an inherited eye condition caused by biallelic mutations in the ABCA4 gene. It typically begins in childhood or adolescence and leads to gradual damage of the macula, resulting in a progressive decline in central vision over time. Currently, there are no FDA-approved treatments available for this rare eye disease.
Year to date, shares of Ocugen have gained 32.6% compared with the industry’s 4.6% growth.
Image Source: Zacks Investment Research
Key Highlights of OCGN’s Phase II/III GARDian3 Study
The phase II/III GARDian3 study is a randomized, pivotal study evaluating the safety and efficacy of OCU410ST in 63 patients across all forms and stages of Stargardt disease, including pediatric and adult populations.
The participants in the treatment group were given OCU410ST as a one-time subretinal injection using OCGN’s AAV5-based modifier gene therapy platform versus an untreated control group.
The primary endpoint focuses on the reduction in atrophic lesion size at 12 months, while the key secondary endpoints include improvements in best-corrected visual acuity and low-luminance visual acuity. Preservation of the Ellipsoid Zone is also being evaluated as an observational endpoint, serving as an early and meaningful indicator of therapeutic benefit. To date, OCU410ST has demonstrated a favorable safety and tolerability profile, with no serious adverse events of special interest reported.
Ocugen expects interim data from the GARDian3 study in the third quarter of 2026, with top-line data anticipated in the second quarter of 2027. The company targets a mid-2027 biologics license application (BLA) submission for OCU410ST, aligned with its broader goal of filing three BLAs by 2028.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 2.9% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have surged 226.7% over the past year.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $8.99 for 2026. Over the past year, shares of ANIP have rallied 11.3%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
Key Takeaways
Ocugen (OCGN - Free Report) announced that enrollment and dosing have been completed in the phase II/III GARDian3 pivotal confirmatory study evaluating its pipeline candidate, OCU410ST, for the treatment of Stargardt disease. The milestone was achieved in less than nine months, ahead of schedule.
OCU410ST has the potential to address more than 1,200 disease-causing mutations in the ABCA4 gene linked to Stargardt disease and other ABCA4-related retinopathies with a single, one-time treatment.
Stargardt disease type I is an inherited eye condition caused by biallelic mutations in the ABCA4 gene. It typically begins in childhood or adolescence and leads to gradual damage of the macula, resulting in a progressive decline in central vision over time. Currently, there are no FDA-approved treatments available for this rare eye disease.
Year to date, shares of Ocugen have gained 32.6% compared with the industry’s 4.6% growth.
Image Source: Zacks Investment Research
Key Highlights of OCGN’s Phase II/III GARDian3 Study
The phase II/III GARDian3 study is a randomized, pivotal study evaluating the safety and efficacy of OCU410ST in 63 patients across all forms and stages of Stargardt disease, including pediatric and adult populations.
The participants in the treatment group were given OCU410ST as a one-time subretinal injection using OCGN’s AAV5-based modifier gene therapy platform versus an untreated control group.
The primary endpoint focuses on the reduction in atrophic lesion size at 12 months, while the key secondary endpoints include improvements in best-corrected visual acuity and low-luminance visual acuity. Preservation of the Ellipsoid Zone is also being evaluated as an observational endpoint, serving as an early and meaningful indicator of therapeutic benefit. To date, OCU410ST has demonstrated a favorable safety and tolerability profile, with no serious adverse events of special interest reported.
Ocugen expects interim data from the GARDian3 study in the third quarter of 2026, with top-line data anticipated in the second quarter of 2027. The company targets a mid-2027 biologics license application (BLA) submission for OCU410ST, aligned with its broader goal of filing three BLAs by 2028.
OCGN's Zacks Rank & Stocks to Consider
Ocugen currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals (ANIP - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 2.9% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have surged 226.7% over the past year.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $8.99 for 2026. Over the past year, shares of ANIP have rallied 11.3%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.